RIG 200

RIG 200 is an S-nitrosothiol nitric oxide (NO) donor. RIG 200 releases NO through decomposition, activating guanylate cyclase (sGCM) in vascular smooth muscle cells, increasing cGMP levels, and leading to vasodilation. RIG 200 significantly inhibits Collagen (HY-NP003) -induced platelet aggregation in platelet-rich plasma (PRP) . RIG 200 may be used in research on antithrombus[1][2][3].

Product Specifications

CAS Number

[202656-49-3]

UNSPSC

12352005

Target

Guanylate Cyclase; NO Synthase

Related Pathways

GPCR/G Protein; Immunology/Inflammation

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Smiles

CC(O[C@@H]1[C@H]([C@@H](O[C@H](COC(C)=O)[C@H]1OC(C)=O)OC(C)=O)NC([C@H](NC(C)=O)C(C)(C)SN=O)=O)=O

Molecular Formula

C21H31N3O12S

Molecular Weight

549.55

References & Citations

[1]Megson IL, et al. Inhibition of human platelet aggregation by a novel S-nitrosothiol is abolished by haemoglobin and red blood cells in vitro: implications for anti-thrombotic therapy. Br J Pharmacol. 2000 Dec;131 (7) :1391-8. |[2]Sogo N, et al. S-nitrosothiols cause prolonged, nitric oxide-mediated relaxation in human saphenous vein and internal mammary artery: therapeutic potential in bypass surgery. Br J Pharmacol. 2000 Nov;131 (6) :1236-44.|[3]Sogo N, et al. A novel S-nitrosothiol (RIG200) causes prolonged relaxation in dorsal hand veins with damaged endothelium. Clin Pharmacol Ther. 2000 Jul;68 (1) :75-81.